GENPREX RECEIVES SAFETY REVIEW COMMITTEE APPROVAL TO ADVANCE TO HIGHEST DOSE GROUP IN PHASE 1 PORTION OF ACCLAIM-3 CLINICAL TRIAL OF REQORSA® GENE THERAPY IN COMBINATION WITH TECENTRIQ® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER

Reuters · 10/15 13:29

Please log in to view news